Long-term treatment with acylated analogues of apelin-13 amide ameliorates diabetes and improves lipid profile of high-fat fed mice

PloS One
Finbarr P M O'hartePeter R Flatt

Abstract

Previous studies have shown that modified apelin analogues exhibited enzyme resistance in plasma and improved circulating half-life compared to apelin-13. This study investigated the antidiabetic effects of chronic administration of stable long acting fatty acid modified apelin analogues, namely, (Lys8GluPAL)apelin-13 amide and pGlu(Lys8GluPAL)apelin-13 amide, in high-fat fed obese-diabetic mice. Male NIH Swiss mice (groups n = 8) were maintained either on a high-fat diet (45% fat) from 8 to 28 weeks old, or control mice were fed a normal diet (10% fat). When diet induced obesity-diabetes was established after high-fat feeding, mice were injected i.p. once daily with apelin analogues, liraglutide (25 nmol/kg) or saline (controls). Administration of (Lys8GluPAL)apelin-13 amide and pGlu(Lys8GluPAL)apelin-13 amide for 28 days significantly reduced food intake and decreased body weight. Non-fasting glucose was reduced (p<0.01 to p<0.001) and plasma insulin concentrations increased (p<0.01 to p<0.001). This was accompanied by enhanced insulin responses (p<0.01 to p<0.001) and significant reductions in glucose excursion after oral (p<0.01) or i.p. (p<0.01) glucose challenges and feeding. Apelin analogues also significantly improved H...Continue Reading

References

Oct 30, 1998·Biochemical and Biophysical Research Communications·K TatemotoM Fujino
Nov 24, 1998·Metabolism: Clinical and Experimental·B L BlackR S Surwit
May 5, 2001·Biochimica Et Biophysica Acta·Y KawamataM Fujino
Dec 25, 2003·Diabetes Care·Donald S FongUNKNOWN American Diabetes Association
Dec 24, 2004·Diabetes Care·Jorge L GrossThemis Zelmanovitz
Jan 29, 2005·Endocrinology·Jérémie BoucherPhilippe Valet
Dec 29, 2005·Health Care Management Science·Marion S RaunerEva-Maria Pesendorfer
Apr 12, 2007·Obesity·Roland BuettnerL Cornelius Bollheimer
Apr 9, 2008·European Journal of Endocrinology·Isabelle Castan-LaurellPhilippe Valet
Dec 3, 2008·Cell Metabolism·Cédric DrayPhilippe Valet
Oct 29, 2009·American Journal of Physiology. Endocrinology and Metabolism·Patrick YuePhilip S Tsao
Mar 18, 2010·American Journal of Physiology. Endocrinology and Metabolism·Cédric DrayIsabelle Castan-Laurell
Jul 31, 2010·Mediators of Inflammation·Carmela Rita BalistreriGiuseppina Candore
May 24, 2013·International Journal of Molecular Sciences·Isabella SaviniLuciana Avigliano
Aug 15, 2013·The Journal of Endocrinology·Anne-Marie O'CarrollGeorge R Pope
Sep 18, 2013·Nature Reviews. Gastroenterology & Hepatology·Rohit Loomba, Arun J Sanyal
Jul 17, 2014·International Journal of Obesity : Journal of the International Association for the Study of Obesity·C AlfaranoO Kunduzova
Apr 29, 2015·Frontiers in Physiology·Chantal BertrandIsabelle Castan-Laurell
May 13, 2015·Clinical Pharmacology and Therapeutics·C J Bailey
Jun 25, 2015·Expert Review of Cardiovascular Therapy·Eva Winning IepsenJens Juul Holst
Jan 1, 2015·Nature Reviews. Disease Primers·Ralph A DeFronzoRam Weiss
Sep 22, 2016·Molecular Genetics and Metabolism·Haoliang HuLinxi Chen
Nov 7, 2016·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Romain GerbierCatherine Llorens-Cortes
Mar 16, 2017·Hypertension·Francesca SchinzariManfredi Tesauro
Jun 15, 2017·The Journal of Endocrinology·Paul MillarVictor A Gault
Dec 10, 2017·Diabetes Care·UNKNOWN American Diabetes Association
Mar 3, 2018·Diabetes Research and Clinical Practice·N H ChoB Malanda
May 29, 2018·Pharmacology & Therapeutics·Amreen Mughal, Stephen T O'Rourke

❮ Previous
Next ❯

Citations

Dec 21, 2018·Expert Opinion on Therapeutic Targets·Isabelle Castan-LaurellPhilippe Valet
Dec 14, 2018·Environmental Science and Pollution Research International·Raja RezgClaude Knauf
Feb 19, 2020·Expert Opinion on Therapeutic Patents·Conrad Fischer
Mar 27, 2020·Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology·Yan-Yan GuoXin-Mei Liu
Jun 28, 2019·Clinical Medicine Insights. Endocrinology and Diabetes·Ryan A LaffertyNigel Irwin
May 23, 2020·Bioengineering & Translational Medicine·Amrita Banerjee, Jagdish Singh
Dec 19, 2020·Journal of Drug Targeting·Faezeh Almasi, Fatemeh Mohammadipanah

❮ Previous
Next ❯

Software Mentioned

Prism
GraphPad

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Biology of GLP-1

Glucagon-like peptide 1 (GLP-1) plays a role in glucose metabolism, energy homeostasis, and inflammation suppression. GLP-1 receptor signaling has been shown to impact cardiovascular function. This feed focuses on the role of GLP-1 and GLP-1 receptor agonists on cardiovascular biology.

Asprosin

Asprosin is a fasting-induced hormone produced in the white adipose tissue to stimulate the hepatic release of glucose into the bloodstream. Discover the latest research on this protein hormone here.